Infliximab Product Approval Information - Licensing Actions

Proper name: Infliximab
Tradename: Remicade
Manufacturer: Centocor, Inc, Malvern, PA, License #1242
Indication for Use: Reducing signs and symptoms, and inducing and maintaining clinical remission in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy
Approval Date: 6/28/2002
Type of submission: Biologics license application supplement


Approval Letter - (PDF)

Label - (PDF)

Page Last Updated: 05/11/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.